Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
7
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
biotech
bristol-myers squibb
celgene
deals
fda
johnson & johnson
nonalcoholic steatohepatitis
pfizer
abbvie
aducanumab
avexis
biogen
cancer immunotherapy
What
news
7
×
roundup
7
×
bio
drug
nash
fda
approved
biogen
biogen’s
biotech
companies
disease
drugs
help
road
week
according
adu
aducanumab
akcea
alzheimer’s
amyloid
angst
approval
aren’t
august
bagged
beats
bids
billions
biopharmaceutical
brammer
busy
cases
centers
cigarettes
complicated
control
convo
days
Language
unset
Current search:
roundup
×
news
×
" new york blog main "
×
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More